-
公开(公告)号：US20230295267A1
公开(公告)日：2023-09-21
申请号：US18206963
申请日：2023-06-07
Applicant: AMGEN INC.
Inventor： Jeonghoon SUN , Lei-Ting Tony TAM , Mark Leo MICHAELS , Thomas Charles BOONE , Rohini R. DESHPANDE , Yue-Sheng LI , Huiquan HAN
IPC: C07K14/71 , C07K14/495
CPC classification number: C07K14/71 , C07K14/495 , A61K38/00
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
Patent Agency Ranking
公开(公告)号：US20240327526A1
公开(公告)日：2024-10-03
申请号：US18381745
申请日：2023-10-19
Applicant: AMGEN INC.
Inventor： Huiquan HAN , Xiaolan ZHOU , Qing CHEN , Mei-Mei TSAI
CPC classification number: C07K16/2863 , A61P21/00 , C07K16/42 , C07K16/468 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
-
公开(公告)号：US20230201231A1
公开(公告)日：2023-06-29
申请号：US18087345
申请日：2022-12-22
Applicant: AMGEN INC. , Atara Biotherapeutics, Inc.
Inventor： Huiquan HAN , Christopher Michael HAQQ , Isaac CIECHANOVER , Xiaolan ZHOU , John Zhao-Nian LU
IPC: A61K31/704 , A61K45/06 , A61K31/7068 , C07K16/22 , A61K38/17 , A61K39/395
CPC classification number: A61K31/704 , A61K45/06 , A61K31/7068 , C07K16/22 , A61K38/177 , A61K39/3955 , A61K39/39558 , A61K38/1796 , A61K2039/505
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
-
公开(公告)号：US20210340262A1
公开(公告)日：2021-11-04
申请号：US17205144
申请日：2021-03-18
Applicant: AMGEN INC.
Inventor： Huiquan HAN , Xiaolan ZHOU , Qing CHEN , Mei-Mei TSAI
Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
-
公开(公告)号：US20200283504A9
公开(公告)日：2020-09-10
申请号：US16388561
申请日：2019-04-18
Applicant: AMGEN INC.
Inventor： Jeonghoon SUN , Lei-Ting Tony TAM , Mark Leo MICHAELS , Thomas Charles BOONE , Rohini DESHPANDE , Yue-Sheng LI , Huiquan HAN
IPC: C07K14/71 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
公开(公告)号：US20190389932A1
公开(公告)日：2019-12-26
申请号：US16388561
申请日：2019-04-18
Applicant: AMGEN INC.
Inventor： Jeonghoon SUN , Lei-Ting Tony TAM , Mark Leo MICHAELS , Thomas Charles BOONE , Rohini DESHPANDE , Yue-Sheng LI , Huiquan HAN
IPC: C07K14/71 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
-
-
-
-
Search Results
6
records
(took 0.008 seconds)
